The use of nadroparin in clinical practice


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The history of the use of heparins dates back to the 30s of the last century. Commercial heparins are produced from different raw materials and by different technological methods, which determines the difference in their anticoagulant properties. Low molecular weight heparins (LMWH) inhibit mainly the Xa active factor. LMWH have not only an antithrombotic effect. They also have nonanticoagulant properties: inhibition of complement activity; modulation of growth factor; modulation of adhesion molecules and leukocyte migration. In clinical practice in non-surgical patients, LMWH is used for the prevention and treatment of venous thromboembolic complications (VTEC). Such treatment is carried out in therapeutic patients hospitalized with severe heart failure, with severe lung disease with respiratory failure; in patients who are forced to observe bed rest and have one of the following risk factors for VTEC. Moreover, LMWH nadroparin calcium is used to treat COVID-19 in adults. According to a randomized, blind, cross-sectional study of 60 elderly bedridden patients, the tolerance of nadroprin was significantly better than enoxaparin.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Olga Ostroumova

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Dr. med. habil., professor, head of the Department of therapy and polymorbid pathology named after Academician M.S. Vovsi; professor of the Department of clinical pharmacology and propaedeutics of internal diseases

Vasily Butorov

Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia

PhD in Medicine, associate professor, associate professor of the Department of therapy and polymorbid pathology named after Academician M.S. Vovsi

Әдебиет тізімі

  1. McLean J. The discovery of heparin. Circulation. 1959; 19(1): 75-78. https://dx.doi.org/10.1161/01.cir.19.175.
  2. Best C.H. Preparation of heparin and its use in the first clinical cases. Circulation. 1959; 19(1): 79-83. https://dx.doi.org/10.1161/01.cir.19.1.79.
  3. Casu B., Nagg An., Torri G. Re-visiting the structure of heparin. Carbohydr Res. 2015; 403: 60-68. https://dx.doi.org/10.1016Zj.carres.2014.06.023.
  4. Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J. Clin Lab Invest. 1967; 19(2): 190-95. https://dx.doi.org/10.3109/00365516709093501.
  5. Messmore H.L., Coyne E., Wehrmacher W.H. et al. Studies comparing low molecular weigth heparin with heparin for the treatment of thromboembolism: A literature review. Curr Farmac Design. 2004; 10(9): 1001-10. https://dx.doi.org/10.2174/1381612043452802.
  6. Linhardt R.J., Loganathan D., Al-Hakim A. et al. Oligosaccharide mapping of low molecular weight heparins: Structure and activity differences. J. Med Chem. 1990; 33(6): 1639-45. https://dx.doi.org/10.1021/jm00168a017.
  7. Hirsh J. Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126(Suppl. 3): 188-203. https://dx.doi.org/10.1378/chest.126.3_suppl.188S.
  8. Walenga J.M., Jackson C.M., Kessler C.M. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Semin Thromb Hemost. 2011; 37(3): 322-27. https://dx.doi.org/10.1055/s-0031-1274515.
  9. Brown R.A., Allegra L., Matera M.G. et al. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther. 2006; 19(6): 419-24. https://dx.doi.org/10.1016/j.pupt.2006.04.004.
  10. Shastri M.D., Peterson G.M., Stewart N. et al. Nonanticoagulant derivatives of heparin for the management of asthma: Distant dream or close reality? Expert Opin Invest Drugs. 2014; 23(3): 357-73. https://dx.doi.org/10.1517/13543784.2014.866092.
  11. Sohal S.S., Patel R.P., Lean Q.Y. et al. Heparins in ulcerative colitis: Proposed mechanisms of action and potential reasons for inconsistent clinical outcomes. Expert Rev Clin Pharmacol. 2015; 8(6): 795-811. https://dx.doi.org/10.1586/17512433.2015.1082425.
  12. Iraji F., Asilian A., Saeidi A. et al. Comparison of therapeutic effect of low-dose low-molecular weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial. Adv Biomed Res. 2013; 2: 76. https://dx.doi.org/10.4103/2277-9175.115798.
  13. Бокерия Л.А., Затевахин И.И., Кириенко А.И. с соавт. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 9(4-2): 1-52. [Bokeriya L.A., Zatevakhin I.I., Kirienko A.I. et al. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya = Phlebology. 2015; 9(4-2): 1-52 (In Russ.)]. EDN: XIOPYZ.
  14. Сомонова О.В., Антух Э.А., Долгушин Б.И. с соавт. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных (RUSSCO). Злокачественные опухоли. 2020; 10(3s2): 131-140. [Somonova O.V., Antukh E.A., Dolgushin B.I. et al. Practical guidelines for the prevention and treatment of thromboembolic complications in cancer patients (RUSSCO). Zlokachestvennyye opukholi = Malignant Tumors. 2020; 10(3s2): 131-140 (In Russ.)]. https://dx.doi.org/10.18027/2224-5057-2020-10-3s2-47.
  15. Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J. Surg. 2001; 88(7): 913-30. https://dx.doi.org/10.1046/j.0007-1323.2001.01800.x.
  16. Simonneau G., Laporte S., Mismetti P. et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J. Thromb Haemost. 2006; 4(8): 1693-700. https://dx.doi.org/10.1111/j.1538-7836.2006.02083.x.
  17. Sadowsk R., Gadzata-Kopciuch R., Kowalkowski T. et al. Characterization of low-molecular-weight heparins by strong anion-exchange chromatography. J. AOAC Int. 2017; 100(6): 1706-14. https://dx.doi.org/10.5740/jaoacint.17-0217.
  18. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 13 (14.10.2021). Минздрав России. Доступ: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (дата обращения - 14.06.2022).
  19. Регистрационное удостоверение ЛП-№(000337)-(РГ-RU) от 27.08.2021.
  20. Albanese C., Bellani M., Longatti S. et al. Comparison of the local tolerability of two subcutaneous low molecular weight heparins: CY216 and enoxaparin. Curr Ther Res. 1992; 51(3): 469-75. https://dx.doi.org/10.1016/0140-6736(92)91054-c.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>